Pt Daewoong Infion (Indonesia)

Daewoong Infion is primarily engaged in medicinals and botanicals activity. Its headquarters is located in Jawa Timur. The company was founded in 2013. Daewoong Infion is a joint venture between Daewoong Pharmaceutical Co., Ltd., a leading South Korean pharmaceutical company, and Infion, an Indonesian pharmaceutical firm. The collaboration aims to leverage Daewoong's advanced pharmaceutical technologies and Infion's local market expertise to produce high-quality biopharmaceutical products. The company focuses on the production of erythropoietin, a critical medication used to treat anemia, particularly in patients with chronic kidney disease. This product is marketed under the brand name Eporon. Daewoong Infion's state-of-the-art manufacturing facility in Jawa Timur is equipped with advanced technology to ensure the production of high-quality pharmaceuticals that meet international standards. Daewoong Infion has a significant presence in the Indonesian market and is expanding its footprint across Southeast Asia. The company is committed to enhancing healthcare accessibility and improving patient outcomes through its innovative products. In addition to its primary focus on erythropoietin, Daewoong Infion is exploring opportunities to expand its product portfolio to include other biopharmaceuticals. The company is also actively seeking partnerships and collaborations with other pharmaceutical companies and research institutions to drive innovation and growth. Daewoong Infion is a member of several industry associations and participates in various healthcare and pharmaceutical forums to stay at the forefront of industry trends and developments. The company's mission is to contribute to the betterment of global health by providing innovative and accessible healthcare solutions.